Date post: | 14-Apr-2017 |
Category: |
Health & Medicine |
Upload: | cmid |
View: | 550 times |
Download: | 5 times |
Rituximab e Polineuropatie da
anticorpi anti-MAGanticorpi anti-MAG
Dott.ssa Luana Benedetti
U.O Neurologia Osp.Sant’Andrea La Spezia
Università di Genova
Polineuropatia da Ab anti-MAG
1. 80% associata MGUS Ig M, 20% M. Waldenstrom
2. +++ uomini; età 60-70 aa
3. Andamento lento progressivo ma invalidante3. Andamento lento progressivo ma invalidante
4. +++ sensitiva; interessamento motorio compare tardi
5. ENG: demielinizzante; TLI < 0.25
6. Patogenesi: IgM dirette contro la MAG
7. Biopsia nervo: slamellamento guaine mieliniche
Depositi Ig M a livello guaine mieliniche
IF indiretta
Microscopio
elettronico
Terapia delle polineuropatie da Ab anti-MAG
• Plasmaferesi
• Immunoglobuline e.v
• Interferone alfa
• Ciclosporina
RITUXIMAB
Anticorpo monoclonale chimerico anti CD20
MECCANISMO D’AZIONEMECCANISMO D’AZIONE
CD 20CD 20
Department of Neurosciences, Ophthalmology and Genetics, University of Genova
Department of Neurosciences, University of Padova
Department Neurological Sciences, Ospedale Maggiore Policlinico, Milano
Neurologia I, Department of Neurosciences, A.S.O. San Giovanni Battista, Torino
Neuromuscolar Diseases Unit, Ce.S.I, Foundation University “G. D’Annunzio”, Chieti
Department Neurological Sciences, IRCCS Humanitas Clinical Institute, Milano
JJournal Peripheral Nervous System Jun 2007;12:102-107
Clinical/Scientific Notes Neurology 2008, 71:1742-1744
Long-term effect of Rituximab in anti-MAG polyneuropathy
L. Benedetti, C. Briani, D. Franciotta, M. Carpo, L. Padua, G. Zara, R. Zambello, M.P Sormani, GL. Mancardi, E.Nobile-Orazio, A. Schenone
Clinical/Scientific Notes Neurology 2008, 71:1742-1744
Long-term effect of Rituximab in anti-MAG polyneuropathy
L. Benedetti, C. Briani, D. Franciotta, M. Carpo, L. Padua, G. Zara, R. Zambello, M.P Sormani, GL. Mancardi, E.Nobile-Orazio, A. Schenone
Risultati relativi al trattamento di 26 pazienti.
Follow-up 12 mesi
1° parte della presentazione
Risultati del follow-up a 36 mesi
2° parte della presentazione
Risultati relativi al trattamento di 26 pazienti.
Follow-up 12 mesi
1° parte della presentazione
JJournal Peripheral Nervous System Jun 2007;12:102-107
Patients
Age Disease duration
IgM Anti-MAG Ab
MRC ISS INCAT Ulnar VCM
Ulnar DML
� 26 affected by anti-MAG polyneuropathy
� 16 M, 10 F
� 20 affected by MGUS, 6 by malignant hematological disease
duration Ab VCM DML
Min 44 0.5 164 1/
1600
46 3 1 12 3.9
Max 73 16 1900 1/
12800000
60 15 8 59.2 14.5
Median 62 8 511 1/
51200
56.50 9 3 35 6
1. Treatment: Rituximab 375 mg/sqm/week x 4 weeks
• MRC Sum Score
• INCAT Disability Scale
• Ig M levels
• CD 19+ B-cells
Immunological evaluation Clinical and electrophysiological evaluation
Methods
2. Evaluation
• INCAT Disability Scale
• ISS- INCAT Sensory Scale
• MCV, DML ulnar, peroneal nerve
• CD 19+ B-cells
• Anti-MAG Ab titers
3. Statistical analysis
Wilcoxon test
Non parametric Spearman rank correlation coefficient
Quality of life (QoL): SF-36
IMMUNOLOGICAL RESULTS
CD19+ B-cells
8
10
12
14
% B
-cel
l CD
19+
CD19+ B-cells were undetectable after one month and returned to pre-treatment values after 9-12 months
0
2
4
6
0 1 3 6 12
months
% B
-cel
l CD
19+
IMMUNOLOGICAL RESULTS
IgM Anti-MAG
Significant reduction of 33% (p<0.001) Significant reduction of 81% (p=0.001)
Baseline 12 months Baseline 12 months
CLINICAL RESULTS
MRC ISS
Significant improvement of 3% (p=0.03)Significant improvement of 20% (p=0.008)
INCAT
Significant improvement of 6% (p=0.05)
� 16 pt (62%) improved in at least 2 scales
� 6 (23%) were unchanged
� 4 (15%) worsened in at least 2 scales
ELECTROPHYSIOLOGICAL RESULTS
• MCV >10% on peroneal nerve in 27% pt, on ulnar nerve in 35% pt
• DML >10% on peroneal in 88% pt, on ulnar nerve in 42% pt
� Significant improvement of 25% (p=0.001) in peroneal DML
� Significant improvement of 7% (p=0.05) in ulnar DML
� Significant improvement of 3.3% (p=0.012) in ulnar MCV
INCAT improvement correlates with. . .
MRC improvement
ISS improvement
R=-0.4, p=0.04 R=0.6, p=0.001
INCAT improvement correlates with. . .
IgM improvement
Anti-MAG title improvement
R=0.65.4, p<0.001 R=0.44, p=0.02
INCAT improvement correlates with. . .
Ulnar MCV improvement
R=-0.3.4, p=0.05
RISULTATIFattori che influenzano la risposta
-0,2
0
0,2
0,4
% IS
S c
han
ge
Il miglioramento clinico correla in modo significativo con un più basso titolo di Ab anti-MAG al baseline
-0,8
-0,6
-0,4
Ab anti-MAG baseline (log scale)
% IS
S c
han
ge
R=0.67, p=0.03
RISULTATIFattori che influenzano la risposta
1. Durata di malattia: R= 0.4, p=0.16
2. Livello Ig M al T0: R= 0.6, p=0.08
3. VCM al T0: R= -0.5, p=0.2
4. cMAP al T0: R= -0.6, p=0.07
Buoni indici di correlazione ma non raggiungono significatività
Basso n° pazienti trattati ?
RISULTATI
EFFETTI COLLATERALI
1. Un pz cefalea, regredita rallentando velocità di infusione
2. Un pz brivido, regredito con terapia 2. Un pz brivido, regredito con terapia steroidea
3. Un pz lieve, transitoria e reversibile leucopenia
4. No eventi avversi maggiori
Risultati del follow-up a 36 mesi
2° parte della presentazione
Clinical/Scientific Notes Neurology 2008, 71:1742-1744
Long-term effect of Rituximab in anti-MAG polyneuropathy
L. Benedetti, C. Briani, D. Franciotta, M. Carpo, L. Padua, G. Zara, R. Zambello, M.P Sormani, GL. Mancardi, E.Nobile-Orazio, A. Schenone
Clinical/Scientific Notes Neurology 2008, 71:1742-1744
Long-term effect of Rituximab in anti-MAG polyneuropathy
L. Benedetti, C. Briani, D. Franciotta, M. Carpo, L. Padua, G. Zara, R. Zambello, M.P Sormani, GL. Mancardi, E.Nobile-Orazio, A. Schenone
Long-term follow-up
12 patients
2 Non Responders
Retreated
0 6 12 24 36
1
2
44
48
52
56
60
0 6 12 24 36
1
2
1/64000001/1600000
1/512001/800000
1/25600
Ab anti-MAG MRC
*
*
Non responder patients to the 1st cycle and retreated
0 6 12 24 36
months months
0
2
4
6
8
10
12
14
16
18
0 6 12 24 36
months
1
2
012345678
0 6 12 24 36
months
1
2
* Retreatment at 12 month. There was progressive worsening in all scales
ISS INCAT
**
Long-term follow-up
12 patients
2 Non Responders
Retreated
10 Responders
Pt(sex,age)MRC INCAT ISS
T0 T12 T24 T36 T0 T12 T24 T36 T0 T12 T24 T36
1 (M, 48) 58 60 60 58 3 0 0 3 7 3 3 6
2 (M, 66) 54 56 50 50 4 3 6 6 12 12 16 16
3 (F, 64) 58 59 59 47 3 3 2 4 11 10 6 12
4 (F, 73) 58 60 60 60 2 1 1 1 8 2 2 2
Responder Patients
4 (F, 73) 58 60 60 60 2 1 1 1 8 2 2 2
5 (F, 57) 59 60 60 60 3 2 2 2 9 6 6 6
6 (M, 69) 59 60 60 60 2 1 1 1 10 5 5 5
7 (M, 70) 60 60 60 60 1 0 0 0 4 2 2 2
8 (M, 66) 46 50 54 54 8 7 4 4 9 8 5 5
9 (M, 82) 51 55 55 55 5 4 5 5 10 10 12 12
10 (F, 63) 56 59 59 59 4 2 2 2 7 6 6 6
Pt(sex,age)MRC INCAT ISS
T0 T12 T24 T36 T0 T12 T24 T36 T0 T12 T24 T36
1 (M, 48) 58 60 60 58 3 0 0 3 7 3 3 6
2 (M, 66) 54 56 50 50 4 3 6 6 12 12 16 16
3 (F, 64) 58 59 59 47 3 3 2 4 11 10 6 12
4 (F, 73) 58 60 60 60 2 1 1 1 8 2 2 2
Responder Patients
4 (F, 73) 58 60 60 60 2 1 1 1 8 2 2 2
5 (F, 57) 59 60 60 60 3 2 2 2 9 6 6 6
6 (M, 69) 59 60 60 60 2 1 1 1 10 5 5 5
7 (M, 70) 60 60 60 60 1 0 0 0 4 2 2 2
8 (M, 66) 46 50 54 54 8 7 4 4 9 8 5 5
9 (M, 82) 51 55 55 55 5 4 5 5 10 10 12 12
10 (F, 63) 56 59 59 59 4 2 2 2 7 6 6 6
Long-term follow-up
12 patients
2 Non Responders
Retreated
10 Responders
6 No retreated
55
56
57
58
59
60
61
0 6 12 24 36
months
1
2
3
4
5
6
Responder patients at 1st cycle, fw-up 36 months
0 6 12 24 36
months
1
2
3
4
5
6
1/200000
1/51200
1/64001/3200
1/1000
Ab anti-MAG MRC
<1/1000
months
0
2
4
6
8
10
12
0 6 12 24 36
months
1
2
3
4
5
60
1
2
3
4
5
0 6 12 24 36
months
1
2
3
4
5
6
months
ISS INCAT
4/6 increase anti-MAG Ab at 24 month. 6/6 clinical stability at 36 months
Long-term follow-up
12 patients
2 Non Responders
Retreated
10 Responders
4 Retreated for relapse
2 at month 24 2 at month 36
6 No retreated
0 6 12 24 36
months
1
2
3
4
48505254565860
0 6 12 24 36
1
2
3
4
Responders at 1st cycle, retreated x relapse
1/8000001/4000001/200000
1/512001/100000
1/256001/128001/6400
anti-MAG Ab MRC
monthsmonths
0
2
4
6
8
10
12
14
16
18
0 6 12 24 36
months
1
2
3
4
0
1
2
3
4
5
6
7
0 6 12 24 36
months
1
2
3
4
Patients were retreated at 36 month with beneficial results
ISS INCAT
LONG-TERM (36 months) RESULTS
1. Clinical improvement persisted in 6 patients2. 4 patients relapsed at months 24-36
CLINICAL RESULTS
IMMUNOLOGICAL RESULTS
1. IgM levels remained decreased by ~60% (p=0.005)2. Anti-MAG titers were still reduced by ~70% (p=0.12)3. but in 8 pt, anti-MAG Ab raised during the fw-up
Pt with relapse vs pt without relapse
1. All the 4 patients who relapsed had baseline anti-MAG titres ≥1/100,000 (median 100,000 ± 175,000)
2. none of the others had titres higher than 1/51,200 (median 27200 ± 10875, Mann-Whitney test, p=0.009)
Quality of life. SF-36
Wilcoxon Test
N T Z p-level
phy fun & phy fun 7 0,00000 2,201398 0,027709
rol phy & rol phy 7 0,00000 2,201398 0,027709
bod pain & bod pain 7 0,00000 2,366432 0,017961
gen hea & gen hea 7 0,00000 2,366432 0,017961
QoL assessment
showed significant
improvement of gen hea & gen hea 7 0,00000 2,366432 0,017961
vit & vit 7 0,00000 2,366432 0,017961
soc fun & soc fun 7 0,00000 2,366432 0,017961
rol emo & rol emo 7 0,00000 2,201398 0,027709
men hea & men hea 7 0,00000 2,366432 0,017961
phy com sc & phy com sc 7 0,00000 2,366432 0,017961
men com sc & men com sc 7 0,00000 2,366432 0,017961
improvement of PCS and MCS
at follow-up (both p=0.02).
CONCLUSION (1)
• CD19+ B-cells were undetectable after 1 month, reappeared after 9-12 months
• Significant reduction of IgM levels (33%) (p<0.001)
• Significant reduction of anti-MAG Ab (81%) (p=0.001)
Immunological results
Patients: 26Follow-up: 12 months
Clinical results
� 16 pt (62%) improved in at least 2 scales
� 6 (23%) were unchanged
� 4 (15%) worsened in at least 2 scales
The % of responders (62%) was the similar of that previously reported
66% Renaud et al. Muscle&Nerve 2003; 75% Dalakas et al. Ann Neurol 2006
(80%) showed clinical stability for 24 months
(60%) showed clinical stability for 36 months
1. In non-responder patients . . . Retreatment was not useful
4. Responder patients can remain stable for a long time
CONCLUSION (2) Long-term follow-up
Garcia-Chavez J et al. Ann Hematol 2007
2. Responder patients can present a clinical or immunological relapse
4. A single rituximab course may induce QoL benefit
5. The 1st and 2nd treatment were safe:no major adverse effects were reported
In 8/10 Anti-MAG Ab increased after 24 months
In 4 patients there was a clinical relapse
3. In responder patients with relapse. . . Retreatment was useful
Based on our results:
SPECULATIONS� Clinical improvement correlated with lower anti-MAG Ab titers at baseline
� Clinical deterioration in responder pt correlated with both high baseline anti-MAG titres and their increase during follow-up
Based on our results:
1. Rituximab may be particularly effective in
patients with low antibody titre and in the early
course of the disease
2. Patients with baseline very high anti-MAG titre
may require additional rituximab courses, both as
induction and as maintenance therapy.
Zaja F et al. Exp Hematol 2006
Renaud S et al. Neurology 2006
GRAZIE
PER PER
L’ATTENZIONE